1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE Chemical Properties

Melting point:

118-121℃

Density 

1.21±0.1 g/cm3(Predicted)

RTECS 

GW1485000

storage temp. 

Sealed in dry,Room Temperature

solubility 

DMSO: 9 mg/mL

form 

solid

pka

13.81±0.46(Predicted)

color 

white

Stability:

Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months

Safety Information

Safety Statements 

22-24/25

WGK Germany 

3

MSDS

• Language:English Provider:SigmaAldrich

1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE Usage And Synthesis

Description

RHC-80267 (83654-05-1) inhibits DAG Lipase activity in a variety of cell types and tissues, including canine platelets, bovine adrenal chromaffin cells, human adrenal glomerulosa cells, rat thyroid lobes and pancreatic minilobules. IC50 in canine platelets is 4 μM.1

Uses

RHC-80267 is a selective inhibitor of DAG lipase, which plays an important role in the production of arachidonic acid.

Definition

ChEBI: N-[6-[[(cyclohexylideneamino)oxy-oxomethyl]amino]hexyl]carbamic acid (cyclohexylideneamino) ester is a carbamate ester and an organonitrogen compound.

General Description

Selective inhibitor of DAG lipase activity in canine platelets (IC₅₀ = 4 nM) and in a variety of mammalian cells. Also inhibits glucose- and carbachol-induced insulin release from intact islets. An inhibitor of Angiotensin II (Cat. No. 05-23-0101) and ATP-induced synthesis of 6-keto-prostaglandin F1α.

Biological Activity

Inhibitor of diacylglycerol lipase (IC 50 values are 1.1 and 4 μ M in rat cardiac myocytes and canine platelets respectively). Weakly inhibits phospholipases C and A 2 . Potentiates acetylcholine evoked relaxation in mesenteric arteries by the inhibition of cholinesterase activity (IC 50 = 4 μ M).

Biochem/physiol Actions

Product does not compete with ATP.

storage

Store at +4°C

References

[1] PAUL W. MANLEY. Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors[J]. Journal of Medicinal Chemistry, 2002, 45 26: 5687-5693. DOI:10.1021/jm020899q
[2] PAUL WILLIAM MANLEY. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis[J]. Biochimica et biophysica acta. Proteins and proteomics, 2004, 1697 1: Pages 17-27. DOI:10.1016/j.bbapap.2003.11.010
[3] PAUL W. MANLEY. Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors[J]. Journal of Medicinal Chemistry, 2002, 45 26: 5687-5693. DOI:10.1021/jm020899q
[4] PAUL WILLIAM MANLEY. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis[J]. Biochimica et biophysica acta. Proteins and proteomics, 2004, 1697 1: Pages 17-27. DOI:10.1016/j.bbapap.2003.11.010
[5] PAUL W. MANLEY. Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors[J]. Journal of Medicinal Chemistry, 2002, 45 26: 5687-5693. DOI:10.1021/jm020899q

1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE(83654-05-1)Related Product Information

• Fatostatin A
• MK-886
• EPOXOMICIN
• (E)-3-[[[3-[2-(7-CHLORO-2-QUINOLINYL)ETHENYL]PHENYL]-[[(3-DIMETHYLAMINO)-3-OXOPROPYL]THIO]METHYL]THIO]-PROPANOIC ACID, SODIUM SALT
• N,N'-DIFORMYL-1,6-DIAMINOHEXANE
• 1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE
• Cyclohexanone oxime